Write your message
Volume 4, Issue 1 (Winter 2019)                   jogcr 2019, 4(1): 36-41 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Behnam Far F, Eghbali K, Mousavi Seresht L. Assessment of Response Rate in Patients with Gestational Trophoblastic Neoplasia: A Case Study of Healthcare Centers in Isfahan from 2011 to 2016. jogcr. 2019; 4 (1) :36-41
URL: http://jogcr.com/article-1-220-en.html
1- Department of Obstetrics & Gynecology, Shahid Beheshti Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2- School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , kh.eghbali72@gmail.com
Abstract:   (217 Views)

Background: Gestational trophoblastic neoplastic (GTN) as the one of curable malignancy all around the world has higher incidence rate in developing country, so study on its behavior, risk factor, and treatment failure reason is encouraging in such countries
Methods: This study was a descriptive, cross-sectional study which tries to examine the GTN cases medical record in referral university hospitals in Isfahan from 2011 to 2016 to examine the risk factor and the factor that affecting treatment response rate. The patients were studied in two divided group based on the FIGO scoring system.
Results: 70 GTN patients were identified over these 5 years. 59 patients were in the low-risk group and 11 patients were in the high-risk group. 100% of the patients in the low-risk group and 90.1% of the patients in the high-risk group responded to the first and second line treatment. In the follow-up one case of recurrence within the low risk patient and one case of mortality from the high-risk patients was reported. In the high-risk metastatic group, there was 1 case of unusual metastasis site at the kidney and the commonest site of distant metastasis was lung.
Conclusion: Response rate in the low-risk GTN patients was excellent (100%) and it was more than 90% in the high-risk GTN patients. Therefore, if GTN patients are treated in reference centers, the response rate will be favorable. Patients with brain metastases have good chances of recovery if treated timely.

Full-Text [PDF 289 kb]   (11 Downloads) |   |   Full-Text (HTML)  (35 Views)  

Response rate in the low-risk GTN patients was excellent (100%) and it was more than 90% in the high-risk GTN patients. Therefore, if GTN patients are treated in reference centers, the response rate will be favorable. Patients with brain metastases have good chances of recovery if treated timely.


Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2018/09/2 | Accepted: 2019/01/12 | Published: 2019/03/1

References
1. Salehi M, Homayi F, Salehi M, editors. Evaluation of gestational choriocarcinoma in oncology department of Qhaem and Omid hospitals-Mashhad(1991-2001): Mashhad university of medical sciences.
2. Gueye M, Ndiaye-Gueye MD, Kane-Gueye SM, Gassama O, Diallo M, Moreau JC. Diagnosis, Treatment and Outcome of Gestational Trophoblastic Neoplasia in a Low Resource Income Country. International journal of MCH and AIDS. 2016;5(2):112-8. [DOI:10.21106/ijma.108] [PMID] [PMCID]
3. Ngan H, Bender H, Benedet J, Jones H, Montruccoli G, Pecorelli S, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. International Journal of Gynecology & Obstetrics. 2003;83:175-7. [DOI:10.1016/S0020-7292(03)90120-2]
4. Santaballa A, García Y, Herrero A, Laínez N, Fuentes J, De Juan A, et al. SEOM clinical guidelines in gestational trophoblastic disease (2017). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018;20(1):38-46. [DOI:10.1007/s12094-017-1793-0] [PMID] [PMCID]
5. Behnamfar F, Mousavi A, Rezapourian P, Zamani A. Placental site trophoblastic tumor, report of a case with unusual presentation. Placenta. 2013;34(5):460-2. [DOI:10.1016/j.placenta.2013.01.010] [PMID]
6. Sasaki K, Hata H, Nakano R. ABO blood group in patients with malignant trophoblastic disease. Gynecologic and obstetric investigation. 1985;20(1):23-6. [DOI:10.1159/000298967] [PMID]
7. Novak E. Berek & Novak's gynecology: Lippincott Williams & Wilkins; 2007.
8. Hussain A, Aziz SA, Bhatt GM, Lone AR, Hussain HI, Wani B, et al. Gestational Trophoblastic Neoplasia: Experience from a Tertiary Care Center of India. Journal of obstetrics and gynaecology of India. 2016;66(6):404-8. [DOI:10.1007/s13224-015-0710-0] [PMID] [PMCID]
9. Parazzini F, La Vecchia C, Franceschi S, Pampallona S, Decarli A, Mangili G, et al. ABO blood-groups and the risk of gestational trophoblastic disease. Tumori. 1985;71(2):123-6. [DOI:10.1177/030089168507100206] [PMID]
10. Cakmak B, Toprak M, Nacar MC, Köseoğlu RD, Güneri N. Incidence of gestational trophoblastic disease in Tokat province, Turkey. Journal of the Turkish German Gynecological Association. 2014;15(1):22-4. [DOI:10.5152/jtgga.2014.81205] [PMID] [PMCID]
11. Aznab M, Nankali A, Daeichin S. Determination of Clinical Process and Response Rate to Treatment in Patients with Gestational Trophoblastic Neoplasia (GTN) with Low and High Risk and Evaluation of Their First Pregnancy Outcome. International journal of hematology-oncology and stem cell research. 2018;12(4):291-7. [DOI:10.18502/ijhoscr.v12i4.107] [PMID] [PMCID]
12. Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. British journal of cancer. 2003;89(12):2197-201. [DOI:10.1038/sj.bjc.6601422] [PMID] [PMCID]
13. Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(7):2636-43. [DOI:10.1200/JCO.1997.15.7.2636] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.